MannKind News

Instead, those predictions swung and missed. The U.S. Food and Drug Administration recently approved the inhaled insulin.

What's taking so long? I jest. But I'm allowed to. MannKind has been talking about a partnership since before the FDA first rejected the drug f Without a doubt, a partnership is the next big catalyst for the stock now that Afrezza is approved.

On June 27, the US Food and Drug Administration approved Afrezza, a first-in-class inhalable insulin/inhaler combination, for adults with diabetes.

MannKind CFO Matthew J. Pfeffer sold 20,000 shares of the company's stock in a transaction dated Tuesday, July 1st.

MannKind Corporation is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

MannKind COO Hakan Edstrom purchased 1,692 shares of MannKind stock in a transaction dated Monday, June 30th.

June 30, 2014 -- Millions of people with type 1 or type 2 diabetes will have another treatment option now that the FDA has approved an inhaled insulin .

Despite the FDA-inspired boost, though, MNKD bears don't seem to be panicking just yet.

In a report published Tuesday, MLV & Co analyst Graig C. Suvannavejh downgraded the rating on MannKind Corporation from Buy to Hold, but raised the price target from $10.00 to $11.00.

The US markets are mixed this afternoon, with the Dow down 0.02%, the S&P up 0.12% and the Nasdaq higher by 0.43%.

Afrezza, a fast-acting form of insulin, for adults with the most common form of diabetes, which affects more than 25 million Americans.

With minutes remaining in the trading day for Monday, the Dow traded down 0.13 percent to 16,830.49 while the NASDAQ surged 0.31 percent to 4,411.75.

MannKind shares were up 9.7% on Monday after Brinson Patrick raised their price target on the stock from $12.00 to $15.00, American Banking News reports.

Shares of MannKind jumped 10% in after-hours trading following the conditional FDA approval for Afrezza.

The third time's the charm for this new formulation of inhalable insulin, the second-ever to make it through the U.S. regulatory process after Pfizer's failed Exubera the better part of a decade ago.

Fast-acting Afrezza is the size of a referee whistle, making it more convenient to carry around than traditionally bottled insulin or the pens.

MannKind Corporation today announced that the U.S. Food & Drug Administration has approved AFREZZA Inhalation Powder to improve glycemic control in adult patients with diabetes mellitus.

The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin device, Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann.

The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin device, Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann.